Filter
159
Text search:
Bedaquiline
Featured
Recommendations
28
New Publications
51
Language
Document type
No document type
109
Studies & Reports
17
Guidelines
16
Manuals
8
Fact sheets
5
Situation Updates
2
Training Material
1
Strategic & Response Plan
1
Countries / Regions
Western and Central Europe
16
Eastern Europe
14
India
12
Uganda
3
Asia
3
Ethiopia
2
Germany
2
South Africa
2
South–East Asia Region
2
Latin America and the Carribbean
2
Eastern Europe and Central Asia
2
Russia
2
Nigeria
1
Philippines
1
Nepal
1
Zambia
1
Kenya
1
Bangladesh
1
Malawi
1
Namibia
1
Ukraine
1
Botswana
1
Paraguay
1
Estonia
1
Romania
1
Georgia
1
Global
1
Authors & Publishers
Publication Years
Category
Countries
35
Clinical Guidelines
32
Public Health
2
Pharmacy & Technologies
2
Key Resources
1
Toolboxes
TB
115
HIV
5
AMR
4
Pharmacy
4
Polio
3
Caregiver
2
NTDs
2
Global Health Education
1
COVID-19
1
8–18 December 2015
A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-TB) treatment shows that newer and repurposed drugs produced better outcomes and fewer deaths than older treatments.
The meta-analysis
...
This guide is a resource for physicians and other health care professionals who provide care and treatment to patients with drug-resistant tuberculosis.
For the first time in almost 50 years there are two new drugs for the treatment of drug-resistant TB (DR-TB): bedaquiline and delamanid. There has also been increased attention given to the safety and efficacy of “re-purposed” drugs that have be
...
A survival guide for clinicans.
3rd edition.
HIV & AIDS Treatment in Practice No. 198
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med
...
Las recomendaciones contenidas en este módulo son un componente de las directrices unificadas de la OMS sobre la tuberculosis (TB) y están destinadas principalmente para el uso de los programas nacionales de control de la tuberculosis, los organismos de salud pública y otros interesados clave que
...
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi
...
Framework for implementation.
The END TB Strategy.
